Tag: immune checkpoint inhibitors
Immune checkpoint inhibitors block the checkpoint molecules. Different types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies (as ipilimumab); anti-PD-1 monoclonal antibodies (as pembrolizumab and nivolumab); and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and durmalumab).
16.07.2019
 
Immune checkpoint inhibitors block the checkpoint molecules. Different types of cancer immune checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies (as ipilimumab); anti-PD-1 monoclonal antibodies (as pembrolizumab and nivolumab); and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and durmalumab)
09.07.2019
 
Autoimmune polyendocrine syndrome type 2 (APS-2) is a polygenic disease in which HLA alleles and non-HLA genes determine the targeting of specific tissues by autoreactive T cells, leading to organ-specific autoimmunity.
25.06.2019
 
Myositis as an adverse event of immune checkpoint blockade for cancer therapy; Myositis as a complication of immune checkpoint blockade
01.07.2018